{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:26Z","timestamp":1792788746144,"version":"4.5.0"},"reference-count":44,"publisher":"Informa UK Limited","issue":"21","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo, Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.2217\/fon-2023-0230","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T05:27:49Z","timestamp":1685424469000},"page":"1461-1472","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":51,"title":["TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC"],"prefix":"10.1080","volume":"19","author":[{"given":"Benjamin P","family":"Levy","sequence":"first","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine,\rWashington,\rDC 20016,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7620-0098","authenticated-orcid":false,"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron University Hospital,Vall d\u2019Hebron Institute of Oncology,\rBarcelona,\r08035,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-4462","authenticated-orcid":false,"given":"Martin","family":"Reck","sequence":"additional","affiliation":[{"name":"Lung Clinic Grosshansdorf, Airway Research Center North (ARCN),Grosshansdorf,\r22927,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5586-5138","authenticated-orcid":false,"given":"James CH","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology,National Taiwan University Hospital,\rTaipei,\r106,\rTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Cappuzzo","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori Regina Elena,\rRome\r,\r00144,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Yoneshima","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Graduate School of Medical Sciences,Kyushu University,\rFukuoka,\r812-8582,\rJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, School of Medicine,Tongji University,\rShanghai,\r200092,\rChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Rawat","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc,\rBasking Ridge,\rNJ 07920,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Xie","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc,\rBasking Ridge,\rNJ 07920,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Basak","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc,\rBasking Ridge,\rNJ 07920,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.,\rRahway,\rNJ 07065, USA"},{"name":"AstraZeneca, Gaithersburg,\rMD 20878, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-7464","authenticated-orcid":false,"given":"Jacob","family":"Sands","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute,\rBoston,\rMA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_6_4_1","unstructured":"American Cancer Society\n. Key statistics for lung cancer (2022). https:\/\/www.cancer.org\/cancer\/lung-cancer\/about\/key-statistics.html"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202297"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06738-z"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00934"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02885"},{"key":"e_1_3_6_10_1","first-page":"1","article-title":"Immunotherapy for advanced non-small cell lung cancer: a decade of progress","volume":"41","author":"Shields MD","year":"2021","unstructured":"Shields MD , Marin-AcevedoJA, PelliniB. Immunotherapy for advanced non-small cell lung cancer: a decade of progress. Am. Soc. Clin. Oncol. Educ. Book41, 1\u201323 (2021).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920937902"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4066"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.4103\/apjon.apjon_4_17"},{"key":"e_1_3_6_14_1","volume-title":"Keytruda (pembrolizumab). Prescribing information.","year":"2019","unstructured":"Keytruda (pembrolizumab). Prescribing information. Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc (2019)."},{"key":"e_1_3_6_15_1","volume-title":"Keytruda (pembrolizumab). Summary of product characteristics.","year":"2022","unstructured":"Keytruda (pembrolizumab). Summary of product characteristics. Merck Sharp & Dohme B.V (2022)."},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0600-6"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.02.005"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15647"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2013.1368"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2016.01.032"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12911"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061744"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0206"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.30.2365"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822"},{"key":"e_1_3_6_28_1","unstructured":"ClinicalTrials.gov\n. Study of Dato-DXd plus pembrolizumab vs pembrolizumab alone in the first-line treatment of subjects with advanced or metastatic NSCLC without actionable genomic alterations (TROPION-Lung08) (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05215340"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102395"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0749"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25830"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.376"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2015.12.008"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100260"},{"issue":"10","key":"e_1_3_6_35_1","doi-asserted-by":"crossref","first-page":"S892","DOI":"10.1016\/j.jtho.2021.08.118","article-title":"TROPION-PanTumor01: updated results from the NSCLC cohort of the phase 1 study of datopotamab deruxtecan in solid tumors","volume":"16","author":"Garon EB","year":"2019","unstructured":"Garon EB , JohnsonM, LisbergAEet al. TROPION-PanTumor01: updated results from the NSCLC cohort of the phase 1 study of datopotamab deruxtecan in solid tumors. J. Thor. Oncol.16(Suppl. 10), S892\u2013S893; Abstract MA03.02 (2019).","journal-title":"J. Thor. Oncol."},{"issue":"4","key":"e_1_3_6_36_1","article-title":"Datopotamab deruxtecan in advanced\/metastatic HER2- breast cancer: results from the phase 1 TROPION-PanTumor01 study","volume":"82","author":"Krop I","year":"2022","unstructured":"Krop I , JuricD, ShimizuTet al. Datopotamab deruxtecan in advanced\/metastatic HER2- breast cancer: results from the phase 1 TROPION-PanTumor01 study. Cancer Res.82(Suppl. 4), Abstract GS1-05 (2022).","journal-title":"Cancer Res."},{"key":"e_1_3_6_37_1","volume-title":"Presented at: 2022 World Conference on Lung Cancer.","author":"Levy B","year":"2022","unstructured":"Levy B , Paz-AresL, RixeOet al. TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC. In: Presented at: 2022 World Conference on Lung Cancer.Vienna, Austria, 6\u20139 August 2022. (Abstract MA13.07)."},{"issue":"15","key":"e_1_3_6_38_1","article-title":"BEGONIA: phase 1b\/2 study of durvalumab (D) combinations in locally advanced\/metastatic triple negative breast cancer (TNBC)\u2014initial results from arm 1, d + paclitaxel (P), and arm 6, d + trastuzumab deruxtecan (T-DXd)","volume":"39","author":"Schmid P","year":"2021","unstructured":"Schmid P , ImS-A, ArmstrongAet al. BEGONIA: phase 1b\/2 study of durvalumab (D) combinations in locally advanced\/metastatic triple negative breast cancer (TNBC)\u2014initial results from arm 1, d + paclitaxel (P), and arm 6, d + trastuzumab deruxtecan (T-DXd). J. Clin. Oncol.39(Suppl. 15), Abstract 1023 (2021).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9058"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9619"},{"key":"e_1_3_6_41_1","unstructured":"European Organisation for Research and Treatment of Cancer\n. Questionnaires (2022). https:\/\/qol.eortc.org\/questionnaires\/"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90535-5"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/2055668319892778"},{"key":"e_1_3_6_45_1","unstructured":"EuroQol Research Foundation\n. EQ-5D-5L (2021). https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/"},{"key":"e_1_3_6_46_1","unstructured":"ClinicalTrials.gov\n. Datopotamab deruxtecan (Dato-DXd) and pembrolizumab with or without platinum chemotherapy in 1L non-small cell lung cancer (TROPION-Lung07) (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05555732"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:44:41Z","timestamp":1719110681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":44,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.2217\/fon-2023-0230"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0230","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}